We moreover show that the HER2T construct is minimally immunogenic in 4T1.2 tumours (Figure 3D) and can be expressed at different levels (Figure S1E), which is useful given HER2-low cancers have been recently reclassified as relevant for HER2-targeted therapy (43). The gene discussed is ERBB2; the disease is cancer.